| Lipitor Dosages & Strengths | ||||
|---|---|---|---|---|
| Strength | Format | Route | Strength | Class |
| Lipitor 10 mg | tablet | oral | 1.0 each | OTC |
| Lipitor 20 mg | tablet | oral | 1.0 each | OTC |
| Lipitor 40 mg | tablet | oral | 1.0 each | OTC |
| Lipitor 80 mg | tablet | oral | 1.0 each | OTC |
Posted by pollyanna about 3 hours ago
I have been on Lipitor for almost 5 years. I started with a low dose of 10mg for 3 years but my cholesterol did not come down...
Posted by base77 7 days ago
June 27/09
I am 65 yrs , very active. Play hockey, baseball, slopitch, and jog.
Started on Lipitor 10gm about 5 years ago....
Posted by eileenpatrice 8 days ago
I truly think my rheumatoid arthritis was the result of taking lipitor. Didn't have any symptoms before taking Lipitor but w...
Pfizer: Outsourcing is necessary business - Therapeutics Daily (subscription) (press release)
Basically, he?s saying, get used to it. Pfizer is preparing for the loss of its patent protection on the world?s top-selling drug, Lipitor. The ...
Sun Mar 09 13:28:34 -0400 2008
Pfizer outlines plans to face life after Lipitor to analysts - Pharma Times (subscription)
... are still unsure whther the firm has the means to deal with the patent loss it will face on the cholesterol blockbuster Lipitor (atorvastatin) in 2010. ...
Thu Mar 06 05:52:35 -0500 2008
Pfizer steels itself for Lipitor expiry - Financial Times
... structure would prepare it for the impending expiry of the patent for its blockbuster cholesterol drug Lipitor, worth some $12bn in annual sales. ...
Wed Mar 05 20:53:59 -0500 2008
atorvastatin - The calcium salt form of atorvastatin, a synthetic lipid-lowering agent. Atorvastatin competitively inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, a key step in cholesterol synthesis. Atorvastatin also increases the number of LDL receptors on hepatic cell surfaces to enhance uptake and catabolism of LDL and reduces LDL production and the number of LDL particles. This agent lowers plasma cholesterol and lipoprotein levels and modulates immune responses by suppressing MHC II (major histocompatibility complex II) on interferon gamma-stimulated, antigen-presenting cells such as human vascular endothelial cells. (NCI04)